Repare Therapeutics was co-founded by researchers from Lunenfeld-Tanenbaum Research Institute, University of Toronto and New York University.
Repare Therapeutics, a Canada-based developer of cancer therapies, raised $68m in series A funding yesterday from a consortium that included BDC Capital, the investment arm of state-owned Business Development Bank of Canada.
BDC Capital participated through its Healthcare Venture Fund. It was joined by Fonds de solidarité FTQ, the state-mandated investment arm of the Quebec labour body, and pharmaceutical firm Celgene Switzerland as well as Versant Ventures and MPM Capital, which co-led the round.
Repare Therapeutics, which emerged from stealth…